The Risk of recurrence in prostate cancer
by: Fritz Frei
Prostate cancer disease
Prostate cancer - the most common form of cancer in men is Prostate cancer, the second leading cause of cancer death. The Main risk factors include age (incidence increases in men over the age of 65 years). It is more prevalent in the western world and about 10% of cases can be linked to family history. The recurrance Rate of the prostate cancer is high.
Mostly, the Prostate cancer is a continuum; progressing through localized, locally advanced, advanced and hormone-refractory stages In general it is a slow growing cancer. He is primarily under hormonal control i.e. testosterone. The choice of treatments which include watchful waiting, surgery (prostatectomy), radiotherapy, hormonal therapy and chemotherapy are dependent on the stage of disease.
1. Most important, that If detected early, using PSA determination, DRE examination and biopsies, and treated appropriately, survival rates are excellent.
2. The most critical focus for the treatment of prostate cancer is to treat those cancers where it is necessary.
3. The Decisions about the best management of prostate cancer can be very complex and depend upon the:
- Pathology of the cancer (unlike other cancers, prostate cancer often progresses very slowly)
- The impact that treatment can have on quality of life, including sexual activity
- Stage of the disease (non-metastatic (localized or locally advanced), metastatic or hormone refractory)
- Age and general health of the patients at diagnosis
- Patient’s preference for treatment
- PSA at diagnosis
4. The treatment options for prostate cancer are:
- Deferred treatment often called ‘watchful waiting’ or 'active surveillance'
- Surgery – Radical Prostatectomy
- Radiotherapy – External Beam and/or Brachytherapy
-Hormonal (endocrine) therapy – Androgen Ablation e.g. anti-androgens, medical castration (LHRHa) or surgical castration
- Palliative Therapy e.g. chemotherapy
- Investigational Therapies
Prostate Cancer Recurrence Rates ***
Prostate cancer is now detected at earlier stages due to heightened awareness and improved screening techniques. Despite definitive therapy, cancer cells may remain and can go undetected for years until they develop into metastatic disease. The risk of recurrence is high, suggesting there is a need to improve treatment approaches. Therefore, it is important to predict pathological stage and risk of disease recurrence early, so that appropriate treatment and/or monitoring can be initiated. The result's of all new treatments will bring us in the future the chance of a lower prostate recurrance.
**You can inform you about the recurrence Rates on:
This gives you an overview with a study case – and the results.
Latest Cancer News:
Puma says cancer drug meets trial goal, shares soar
(Reuters) - Puma Biotechnology Inc said its experimental breast cancer drug met its main goal in a late-stage trial. Puma said on Tuesday it plans to file for marketing approval of neratinib, code named PB272, in the first half of 2015. Adjuvant treatment with the drug showed a statistically significant improvement in disease-free survival of 33 percent versus patients on placebo, according to ... Cancer overtreatment must stop
Studies found that a large number of American men with prostate cancer get unnecessary and aggressive treatment, Dr. Otis Brawley says. New Clinical Study Aims to Investigate the Genomics of Young Lung Cancer
The Addario Lung Cancer Medical Institute today launched a new study, the Genomics of Young Lung Cancer, to understand why lung cancer occurs in young adults, who quite often are athletic, never smokers and do not exhibit any of the known lung cancer genetic mutations. BRCA Gene Testing-Based Breast Cancer and Ovarian Cancer Keynote Speaker, Advocate, Advisor and 'Previvor' Launches ...
BRCA gene testing-based breast cancer and ovarian cancer keynote speaker, advocate, advisor and "previvor," Merilee Kern, today announced the launch of the "BRCA Believer" shirt and ... GÉANT: Could Data Sonification Deliver While-You-Wait Cancer Diagnosis?
Converting stem cell data into sounds could enable GPs to make instant, non-invasive cancer diagnoses during a routine check-up. With waiting times for cancer tests at a six-year high, this could significantly reduce the agonising and potentially life-threatening wait for patients Virginia Cancer Specialists Celebrates 40 Years of Patient Care in Northern Virginia
The month of July marks a very important milestone for Virginia Cancer Specialists , a long-standing member of the medical community and the region?s leading cancer care provider. Cancer Genetics, Inc. to Present at the Canaccord Genuity 34th Annual Growth Conference
RUTHERFORD, N.J. -- Cancer Genetics, Inc. ("CGI" or the "Company"), an emerging leader in DNA-based diagnostics, today announced that an overview of the Company's business and commercial ... Inova Comprehensive Cancer and Research Institute Auditorium Named for FOAA Anesthesia Services
FOAA Anesthesia Services , the mid-Atlantic division of North American Partners in Anesthesia , was recently recognized for its contribution to the construction of the Inova Comprehensive Cancer and Research ... Foundation Medicine Partners with the Addario Lung Cancer Medical Institute for Innovative Prospective Study Linking ...
Foundation Medicine, Inc. today announced that it has partnered with the Addario Lung Cancer Medical Institute and Bonnie J. Addario Lung Cancer Foundation to launch a first of its kind, multi-center, international prospective study, the Genomics of Young Lung Cancer. Volunteer efforts help boost childhood cancer research with $250,000 donation
MILWAUKEE, July 23, 2014 /PRNewswire/ -- According to the Pediatric Cancer Foundation, only 3.8 percent of all cancer research funding allocated by the federal government goes to children, despite the fact that childhood cancer is the leading cause of death for kids in the U.S. Northwestern Mutual, through its Foundation, is dedicated to helping find a cure and assisting children battling ... Study Finds New Cancer Risk From Hysterectomy Device - Wall Street Journal